1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Depression in 12 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Depression was induced by a 14-day chronic unpredictable mild stress (CUMS), and PD was induced by 1-day acute injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.62 | Depression Induced by Chronic Unpredictable Mild Stress Increases Susceptibility to Parkinson's Disease in Mice via Neuroinflammation Mediated by P2X7 Receptor. ( Dong, AQ; Hu, H; Li, LX; Liu, CF; Mao, CJ; Ren, C; Wang, F; Zhang, YT, 2021) |
| "Depression is a frequently encountered non-motor feature of Parkinson's disease (PD) and it can have a significant impact on patient's quality of life." | 1.36 | Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. ( Andreatini, R; Barbieiro, J; Dombrowski, PA; Lima, MM; Santiago, RM; Vital, MA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 1 |
| Chen, W | 1 |
| Wang, C | 1 |
| Liu, W | 1 |
| Hayashi, T | 1 |
| Mizuno, K | 1 |
| Hattori, S | 1 |
| Fujisaki, H | 1 |
| Ikejima, T | 1 |
| Yan, J | 1 |
| Huang, J | 1 |
| Liu, A | 1 |
| Wu, J | 1 |
| Fan, H | 1 |
| Shen, M | 1 |
| Lai, X | 1 |
| Ma, H | 1 |
| Sun, W | 1 |
| Yang, J | 1 |
| Xu, Y | 1 |
| Ren, C | 1 |
| Li, LX | 1 |
| Dong, AQ | 1 |
| Zhang, YT | 1 |
| Hu, H | 1 |
| Mao, CJ | 1 |
| Wang, F | 1 |
| Liu, CF | 1 |
| Özkan, A | 1 |
| Bülbül, M | 1 |
| Derin, N | 1 |
| Sinen, O | 1 |
| Akçay, G | 1 |
| Parlak, H | 1 |
| Aydın Aslan, M | 1 |
| Ağar, A | 1 |
| Khlebnikova, NN | 4 |
| Krupina, NA | 4 |
| Bogdanova, NG | 1 |
| Zolotov, NN | 1 |
| Kryzhanovskii, GN | 3 |
| Gorton, LM | 1 |
| Vuckovic, MG | 1 |
| Vertelkina, N | 1 |
| Petzinger, GM | 1 |
| Jakowec, MW | 1 |
| Wood, RI | 1 |
| Santiago, RM | 1 |
| Barbieiro, J | 1 |
| Lima, MM | 1 |
| Dombrowski, PA | 1 |
| Andreatini, R | 1 |
| Vital, MA | 1 |
| Orlova, IN | 2 |
| Grafova, VN | 1 |
| Smirnova, VS | 1 |
| Rodina, VI | 2 |
| Kukushkin, ML | 1 |
| Kryzhanovsky, GN | 1 |
| Pankova, NB | 2 |
| Vetrilé, LA | 1 |
| Basharova, LA | 1 |
| Glover, V | 1 |
| Sandler, M | 1 |
| Stern, Y | 1 |
| Langston, JW | 1 |
12 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Depression
| Article | Year |
|---|---|
Silibinin ameliorates depression/anxiety-like behaviors of Parkinson's disease mouse model and is associated with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Depression; Disease Models, Animal; | 2021 |
Atorvastatin improves motor function, anxiety and depression by NOX2-mediated autophagy and oxidative stress in MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Atorvastatin; Autophagy; Behavior, A | 2020 |
Depression Induced by Chronic Unpredictable Mild Stress Increases Susceptibility to Parkinson's Disease in Mice via Neuroinflammation Mediated by P2X7 Receptor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Depression; Disease Models, Animal; Mice; Mic | 2021 |
Neuropeptide-S affects cognitive impairment and depression-like behavior on MPTP induced experimental mouse model of Parkinson’s disease
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition; Depression; Disease Models, Animal | 2021 |
Effects of prolylendopeptidase inhibitor benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine on experimental depressive syndrome development in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Depression; Male; Methionine; Prolyl Oligopep | 2009 |
Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Behavior, Animal; Brain; Corticoster | 2010 |
Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Depre | 2010 |
Experimental model of combined pain and depression status in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Axotomy; Behavior, Animal; Depressio | 2010 |
Immunization of rats with conjugates of dopamine and serotonin with bovine serum albumin prevents the development of experimental MPTP-induced depressive syndrome (electrophysiological parameters).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Depression; | 2004 |
Involvement of brain dopaminergic systems in the development of an MPTP-induced depressive state in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Brain; Depression; Dopamine Agen | 2008 |
Clinical chemistry of monoamine oxidase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Platelets; Brain; Clorgyline; Depressio | 1986 |
Intellectual changes in patients with MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Attention; Depression; Humans; Intelligence; Pa | 1985 |